CNTA
Centessa Pharmaceuticals plc
39.72
1 x 39.61
1 x 39.78
bid
ask
+
12.14
44.02%
1 @ 04:00 PM
39.95 +0.23 (0.58%)
Ytd 58.82%
1y 176.22%
39.57
day range
40.25
9.60
52 week range
40.25
Open 40.02 Prev Close 27.58 Low 39.57 High 40.25 Mkt Cap 5.87B
Vol 47.69M Avg Vol 1.43M EPS -1.89 P/E N/A Forward P/E -16.78
Beta 1.55 Short Ratio 5.53 Inst. Own 101.82% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 03-31 50-d Avg 25.91 200-d Avg 22.17 1yr Est 40.38
Earning
Date For Estimate Reported Surprise surprise %
2026-03-30 2025-12 0 N/A N/A N/A
2025-11-05 2025-09 0 N/A -0.02 -5.13%
2025-08-12 2025-06 0 N/A N/A N/A
2025-08-12 2025-06 0 N/A -0.03 -8.57%
2025-05-14 2025-03 0 N/A N/A N/A
2025-05-14 2025-03 0 N/A 0.15 42.86%
Upgrade / Downgrade
Date Firm Action From To
2026-03-31 Wolfe Research Downgrade Outperform Peer Perform
2026-03-31 Needham Downgrade Buy Hold
2026-02-24 Wolfe Research Upgrade Outperform
2026-01-29 Truist Securities Upgrade Buy Buy
2026-01-08 Truist Securities Upgrade Buy Buy
2026-01-02 Chardan Capital Upgrade Buy Buy
Profile
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Insider Holder
Date Name Relation Quantity Description
2026-02-01 ACCARDI MARIO ALBERTO Chief Executive Officer 243.89K Stock Award(Grant)
2026-03-25 ANDERSON KAREN M Officer 62.09K Conversion of Exercise of derivative security
2026-02-01 BUSH TIA L Chief Technology Officer 147.95K Stock Award(Grant)
2025-03-16 CHAO DAVID M Officer 225.01K Conversion of Exercise of derivative security
2026-02-01 CROWLEY JOHN JOSEPH CPA Chief Financial Officer 45.00K Stock Award(Grant)
2025-05-15 GOYAL ARJUN Director 0.00 Purchase
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Medicxi Ventures Management (Jersey) Ltd 19.96M 792.94M 13.67%
2025-12-30 Avoro Capital Advisors LLC 14.56M 578.15M 9.97%
2025-12-30 Adage Capital Partners GP L.L.C. 11.28M 448.11M 7.72%
2025-12-30 Index Venture Life Associates VI Ltd 9.96M 395.68M 6.82%
2025-12-30 FMR, LLC 8.96M 355.97M 6.14%
2025-12-30 General Atlantic, L.P. 6.12M 243.00M 4.19%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 T. Rowe Price Health Sciences Fund, Inc. 2.19M 87.16M 1.50%
2026-02-27 Fidelity Select Portfolios-Select Biotechnology Portfolio 2.19M 86.89M 1.50%
2026-02-27 Fidelity Select Portfolios-Select Health Care Portfolio 1.65M 65.54M 1.13%
2026-01-30 Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund 1.24M 49.10M 0.85%
2026-01-30 Fidelity Contrafund 1.23M 48.98M 0.84%
2025-12-30 SmallCap World Fund Inc 1.14M 45.16M 0.78%